This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

This study has been completed.
Information provided by (Responsible Party):
CSL Behring Identifier:
First received: February 26, 2012
Last updated: April 19, 2017
Last verified: March 2013
This is a first in man, prospective, single-center, randomized, double-blind, dose-escalation cohort study to investigate tolerability, safety and pharmacokinetics of rVIIa-FP in comparison to placebo.

Condition Intervention Phase
Healthy Biological: rVIIa-FP Biological: Placebo (0.9% normal saline) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Single Center, 5 Cohort Dose Escalation Trial to Investigate Safety and Pharmacokinetics of rVIIa-FP (CSL689) in Comparison to Placebo in Healthy Male Human Volunteers

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • The frequency of related Adverse Events (AEs) to rVIIa-FP. [ Time Frame: 28 days ]
  • Number of subjects who develop inhibitors against Factor VII (FVII). [ Time Frame: 28 days ]
  • Number of subjects who develop antibodies against rVIIa-FP. [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Area under curve to the last sample with quantifiable drug concentration (AUC0-t) of a single dose of rVIIa-FP [ Time Frame: 120 hours ]
  • Half- life (t1/2) of a single dose of rVIIa-FP [ Time Frame: 120 hours ]
  • Incremental recovery (IR) of rVIIa-FP [ Time Frame: 120 hours ]
  • Clearance (Cl) of a single dose of rVIIa-FP [ Time Frame: 120 hours ]

Enrollment: 40
Study Start Date: March 2012
Study Completion Date: July 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rVIIa-FP Biological: rVIIa-FP
Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
Placebo Comparator: Placebo (0.9% normal saline) Biological: Placebo (0.9% normal saline)
Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects between 18 and 35 years of age, both inclusive.
  • Body weight between 50.0 and 100.0 kg, both inclusive.
  • Body mass index (BMI) between 18.0 and 29.9 kg/m2, both inclusive.
  • Written informed consent for study participation obtained before undergoing any study specific procedures.

Exclusion Criteria:

  • Subjects at increased cardiovascular risk.
  • Any clinical sign or known history of atherosclerosis or thromboembolic events.
  • A subject considered at high risk of thromboembolic events confirmed either from history or by thrombophilia screening test.
  • Subjects with significant elevation of cholesterol level.
  • Renal dysfunction.
  • Overt bleeding.
  • Smokers with positive cotinine test at screening.
  • Participation in any other trial investigating a procoagulant within the last six months prior to screening.
  • Known or suspected hypersensitivity to the investigational medicinal product (IMP), or to any excipients of the IMP.
  • Contraindications to Warfarin (Coumadin®).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01542619

Phase I Unit
Berlin, Germany
Sponsors and Collaborators
CSL Behring
Study Director: Alex Veldman, M.D. CSL Behring
  More Information

Responsible Party: CSL Behring Identifier: NCT01542619     History of Changes
Other Study ID Numbers: CSL689_1001
2011-004568-32 ( EudraCT Number )
Study First Received: February 26, 2012
Last Updated: April 19, 2017 processed this record on September 20, 2017